ArticleThe American Journal of dermatopathology2026
Diagnostic and Prognostic Values of PRAME Immunohistochemistry in Acral Lentiginous Melanoma.
Article in The American Journal of dermatopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPReferentially Expressed Antigen in MElanoma (PRAME) was introduced as an ancillary tool for confirming the diagnosis of cutaneous melanoma, including the acral lentiginous melanoma (ALM). However, its standardized cut-off values and prognostic performance remain inconclusive. This study assessed the diagnostic performance of PRAME immunohistochemistry (IHC) in ALM across different thresholds and explored its prognostic associations.
methodsThis retrospective cohort study reviewed 90 acral melanocytic lesions, including 60 cases of acral benign nevi and 30 cases of primary ALM. PRAME immunohistochemistry was performed on the biopsy specimens. Sensitivity and specificity were calculated at varying cut-offs. The optimal threshold was applied to link PRAME expression with the outcome and features of ALM.
resultsA PRAME staining threshold of 50% (score ≥3) provided the optimum cut-off for differentiating ALM, with a high specificity of 98.3% and sensitivity of 53.3%. Positive PRAME was significantly associated with higher TNM stages (ordinal odds ratio [95% confidence interval], 13.11 [2.55-67.27]) and higher rates of recurrence (hazard ratio, 6.62 [1.42-30.94]) but not with any unfavorable histopathological features or mortality.
conclusionPRAME can be used as an adjunctive diagnostic tool to differentiate malignant from benign acral melanocytic lesions. It may serve as a prognostic marker for poor ALM outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.